摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-氯-3-甲氧基苯硼酸 | 89694-47-3

中文名称
4-氯-3-甲氧基苯硼酸
中文别名
N-(2-羟乙基)哌嗪-N'-(2-羟基丙磺酸)钠盐;4-氯-3-甲氧基苯基硼酸
英文名称
(4-chloro-3-methoxyphenyl)boronic acid
英文别名
3-methoxy-4-chlorophenylboronic acid;4-Chloro-3-methoxyphenylboronic acid
4-氯-3-甲氧基苯硼酸化学式
CAS
89694-47-3
化学式
C7H8BClO3
mdl
——
分子量
186.403
InChiKey
DZNNRXURZJLARZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    151°C(lit.)
  • 沸点:
    341.7±52.0 °C(Predicted)
  • 密度:
    1.32±0.1 g/cm3(Predicted)
  • 溶解度:
    溶于甲醇

计算性质

  • 辛醇/水分配系数(LogP):
    0.03
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    49.7
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2931900090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335

SDS

SDS:c89ef5137629aeaabcec82220bfb30db
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 4-Chloro-3-methoxyphenylboronic acid
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 4-Chloro-3-methoxyphenylboronic acid
CAS number: 89694-47-3

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H8BClO3
Molecular weight: 186.4

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-氯-3-甲氧基苯硼酸三溴化硼 作用下, 以 二氯甲烷 为溶剂, 反应 16.0h, 生成 (4-氯-3-羟基苯基)硼酸
    参考文献:
    名称:
    [EN] HETEROCYCLIC COMPOUNDS AND METHODS OF USE
    [FR] COMPOSÉS HÉTÉROCYCLIQUES ET PROCÉDÉS D'UTILISATION
    摘要:
    本申请公开了抑制Btk的化合物、抑制ΡΒΚδ的化合物,以及既是Btk又是PI3Kδ的双重抑制剂的化合物。还描述了合成这些抑制剂的方法,以及利用这些抑制剂治疗疾病的方法,其中抑制Btk和PI3Kδ对患有该疾病的患者提供治疗益处。
    公开号:
    WO2015058084A1
  • 作为产物:
    描述:
    5-溴-2-氯苯甲醚正丁基锂硼酸三异丙酯盐酸 作用下, 以 乙醚正己烷 为溶剂, 反应 2.5h, 以900 mg的产率得到4-氯-3-甲氧基苯硼酸
    参考文献:
    名称:
    [EN] HETEROCYCLIC COMPOUNDS AND METHODS OF USE
    [FR] COMPOSÉS HÉTÉROCYCLIQUES ET PROCÉDÉS D'UTILISATION
    摘要:
    本申请公开了抑制Btk的化合物、抑制ΡΒΚδ的化合物,以及既是Btk又是PI3Kδ的双重抑制剂的化合物。还描述了合成这些抑制剂的方法,以及利用这些抑制剂治疗疾病的方法,其中抑制Btk和PI3Kδ对患有该疾病的患者提供治疗益处。
    公开号:
    WO2015058084A1
点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED PYRAZOLE AND PYRROLE COMPOUNDS AND METHODS FOR USING THEM FOR INHIBITION OF INITIATION OF TRANSLATION AND TREATMENT OF DISEASES AND DISORDERS RELATING THERETO<br/>[FR] COMPOSÉS PYRAZOLE ET PYRROLE SUBSTITUÉS ET PROCÉDÉS D'UTILISATION DE CES DERNIERS POUR L'INHIBITION DE L'INITIATION DE LA TRADUCTION ET LE TRAITEMENT DE MALADIES ET DE TROUBLES ASSOCIÉS À CETTE DERNIÈRE
    申请人:BANTAM PHARMACEUTICAL LLC
    公开号:WO2016196644A1
    公开(公告)日:2016-12-08
    Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure (I) and pharmaceutically acceptable salts and /V-oxides thereof, wherein X1, X2, Z1, Z2, the ring system denoted by "a", R1, A1A, L1B, A1B, L1A, L2, Q, L3, R3, A4A, L4B, A4B, L4A, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein disrupt the elF4E/eiF4G interaction, and can be used to treat hyperproliferative disorder, a neurological disease or disorder, or autism.
    揭示了吡唑化合物,以及其药物组合物和使用方法。其中一种实施例是具有结构(I)及其药用可接受的盐和/或氧化物,其中X1、X2、Z1、Z2、由“a”表示的环系统、R1、A1A、L1B、A1B、L1A、L2、Q、L3、R3、A4A、L4B、A4B、L4A、R4、L5和R5如本文所述。在某些实施例中,本文所披露的化合物破坏elF4E/eiF4G相互作用,并可用于治疗过度增殖性疾病、神经系统疾病或障碍,或自闭症。
  • [EN] IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS<br/>[FR] IMIDAZOLYL-IMIDAZOLES EN TANT QU'INHIBITEURS DE KINASE
    申请人:GLAXO GROUP LTD
    公开号:WO2011123609A1
    公开(公告)日:2011-10-06
    Disclosed are compounds having the formula: wherein R1A, R1B, R2 and R3 are as defined herein, and methods of making and using the same.
    揭示了具有以下公式的化合物:其中R1A、R1B、R2和R3如本文所定义,并且制备和使用这些化合物的方法。
  • 2-PYRIDONE COMPOUNDS
    申请人:KAWAGUCHI Takanori
    公开号:US20110237791A1
    公开(公告)日:2011-09-29
    A 2-pyridone compound represented by the formula [1]: wherein in the formula [1], the ring represented by A represents a benzene ring or a pyridine ring, X represents any of the structures represented by the formulas [3] shown below: V represents a single bond or a lower alkylene group, and W represents a single bond, an ether bond or a lower alkylene group (wherein the lower alkylene group may contain an ether bond)}, a tautomer or stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is a compound that has an excellent GK activating effect and is useful as a pharmaceutical.
    化学式为[1]所代表的2-吡啶酮化合物: 其中在化学式[1]中, 由A代表苯环或吡啶环表示的环, X代表下面所示的化学式[3]所代表的任意结构: V代表单键或较低的烷基链,以及 W代表单键、醚键或较低的烷基链(其中较低的烷基链可能含有醚键)}, 该化合物的异构体或立体异构体,其药学上可接受的盐,或其溶剂化合物是一种具有出色的GK激活效果并且可用作药物的化合物。
  • Derivatives of m-Guaiacol, Their Preparation and Their Uses
    申请人:Universite de Caen Normandie
    公开号:US20210337789A1
    公开(公告)日:2021-11-04
    The invention concerns derivatives of m-guaiacol, their preparation and their uses as biocides, in particular as antibacterials or disinfectants.
    这项发明涉及对m-石碱生物的制备及其用途,特别是作为抗菌剂或消毒剂。
  • Bicyclic sulfonamide compounds as sodium channel inhibitors
    申请人:AMGEN INC.
    公开号:US09212182B2
    公开(公告)日:2015-12-15
    The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    本发明提供了式I的化合物及其药学上可接受的盐,这些化合物是通道的抑制剂,特别是Nav1.7。这些化合物对于治疗与通道活性相关的疾病,如疼痛障碍和瘙痒,是有用的。还提供了含有本发明化合物的药物组合物。
查看更多

同类化合物

(R)-3-(叔丁基)-4-(2,6-二异丙氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (2S,3R)-3-(叔丁基)-2-(二叔丁基膦基)-4-甲氧基-2,3-二氢苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2R,2''R,3R,3''R)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2-氟-3-异丙氧基苯基)三氟硼酸钾 (+)-6,6'-{[(1R,3R)-1,3-二甲基-1,3基]双(氧)}双[4,8-双(叔丁基)-2,10-二甲氧基-丙二醇 麦角甾烷-6-酮,2,3,22,23-四羟基-,(2a,3a,5a,22S,23S)- 鲁前列醇 顺式6-(对甲氧基苯基)-5-己烯酸 顺式-铂戊脒碘化物 顺式-四氢-2-苯氧基-N,N,N-三甲基-2H-吡喃-3-铵碘化物 顺式-4-甲氧基苯基1-丙烯基醚 顺式-2,4,5-三甲氧基-1-丙烯基苯 顺式-1,3-二甲基-4-苯基-2-氮杂环丁酮 非那西丁杂质7 非那西丁杂质3 非那西丁杂质22 非那西丁杂质18 非那卡因 非布司他杂质37 非布司他杂质30 非布丙醇 雷诺嗪 阿达洛尔 阿达洛尔 阿莫噁酮 阿莫兰特 阿维西利 阿索卡诺 阿米维林 阿立酮 阿曲汀中间体3 阿普洛尔 阿普斯特杂质67 阿普斯特中间体 阿普斯特中间体 阿托西汀EP杂质A 阿托莫西汀杂质24 阿托莫西汀杂质10 阿托莫西汀EP杂质C 阿尼扎芬 阿利克仑中间体3 间苯胺氢氟乙酰氯 间苯二酚二缩水甘油醚 间苯二酚二异丙醇醚 间苯二酚二(2-羟乙基)醚 间苄氧基苯乙醇 间甲苯氧基乙酸肼 间甲苯氧基乙腈 间甲苯异氰酸酯